TG Therapeutics, Inc. (TGTX) saw its loss widen to $24.83 million, or $0.50 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $13.66 million, or $0.28 a share.

Revenue during the quarter was stable at $0.04 million, when compared with the previous year period.

Operating loss for the quarter was $24.93 million, compared with an operating loss of $13.83 million in the previous year period.

Michael S. Weiss, the Company's Executive chairman and chief executive officer, stated, "The third quarter was a pivotal one for the company, particularly with the amendment of the GENUINE Phase 3 trial that will enable the rapid conclusion of the study while also maintaining the possibility for accelerated approval for TG-1101 in combination with ibrutinib. Importantly, with GENUINE enrollment wrapping up, we can dedicate our resources and focus to our proprietary UNITY program, which we believe offers the potential for highly active, well-tolerated therapy with certain pricing advantages over competitors. As a result, we see our value proposition rising as the concern around pharmaceutical pricing continues to grow." Mr. Weiss continued, "We see important value creating milestones over the next 12 months, including completion of enrollment of GENUINE expected by year end 2016 to be followed by top line data in the first half of 2017."